MARKET

RCUS

RCUS

Arcus Bioscience
NYSE
15.62
-0.16
-1.01%
After Hours: 15.50 -0.12 -0.77% 19:39 11/20 EST
OPEN
15.66
PREV CLOSE
15.78
HIGH
16.66
LOW
15.56
VOLUME
1.67M
TURNOVER
--
52 WEEK HIGH
31.74
52 WEEK LOW
15.56
MARKET CAP
2.25B
P/E (TTM)
-4.2894
1D
5D
1M
3M
1Y
5Y
1D
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Barchart · 3d ago
Arcus Biosciences price target lowered to $28 from $29 at BofA
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)
TipRanks · 5d ago
Weekly Report: what happened at RCUS last week (1109-1113)?
Weekly Report · 5d ago
Arcus Biosciences (RCUS) Could Be 57% Undervalued Following Third Quarter Results
Simply Wall St · 11/14 16:26
Arcus Biosciences Stock Faces Revenue Drop And Wider Nine Month Loss
Simply Wall St · 11/13 14:20
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 11/12 21:05
Arcus Biosciences (RCUS) Stock Could Be Cheap Despite A 49% Five Year Fall
Simply Wall St · 11/12 13:23
More
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Webull offers Arcus Biosciences Inc stock information, including NYSE: RCUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RCUS stock methods without spending real money on the virtual paper trading platform.